The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; MSD; National Bioproducts Institute; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca Japan; Bristol-Myers Squibb Japan; Ono Pharmaceutical
Research Funding - AstraZeneca Japan; Bristol-Myers Squibb Japan; Ono Pharmaceutical
TENERGY: Multicenter phase II study of atezolizumab monotherapy following definitive chemoradiotherapy with 5-FU plus cisplatin in patients with locally advanced esophageal squamous cell carcinoma.
 
Hideaki Bando
Research Funding - AstraZeneca; Sysmex
 
Daisuke Kotani
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Chugai Pharma; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Chugai Pharma; Merck Serono; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); Lilly (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Ken Kato
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Keisho Chin
No Relationships to Disclose
 
Kensei Yamaguchi
Consulting or Advisory Role - Bristol-Myers Squibb Japan; Daiichi Sankyo
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Shun-ichiro Kageyama
No Relationships to Disclose
 
Hidehiro Hojo
No Relationships to Disclose
 
Masashi Wakabayashi
Honoraria - Chugai Pharma; Johnson & Johnson
 
Miki Fukutani
No Relationships to Disclose
 
Yosuke Togashi
No Relationships to Disclose
 
Nozomu Fuse
No Relationships to Disclose
 
Hiroyoshi Nishikawa
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Ono Pharmaceutical
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - Asahi Kasei; Astellas Pharma; AstraZeneca; BD Biosciences; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Ono Pharmaceutical; Sysmex; Taiho Pharmaceutical; Zenyaku Kogyo
 
Takashi Kojima
Honoraria - Oncolys BioPharma
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Oncolys BioPharma (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)